In 365 Chinese adults with episodic or chronic migraine, fremanezumab (monthly or quarterly) reduced monthly migraine days more than placebo over 12 weeks (−4.6 vs −2.8; p<0.0001). Any adverse events 47% vs 43%; gains held in a 12-week open-label extension.
RCTn = 365
Yu et al. Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension